My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ProMIS Neurosciences Inc. - Common Shares (NQ:PMN)

0.4088 +0.0098 (+2.46%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ProMIS Neurosciences Inc. - Common Shares

< Previous 1 2 3 Next >
ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer’s Association International Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Announces Private Placement Financing
$3 million private financing plus an additional $9 million of proceeds due to exercise of warrants, for gross proceeds of approximately $12.0 million 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Announces Private Placement Financing
$2.4 million private financing plus an additional $6.8 million of proceeds due to exercise of warrants and $0.8 million from a registered offering for gross proceeds of $9.2 million 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer’s Disease
FDA designation highlights the potential of PMN310 to deliver a more targeted approach to treating Alzheimer’s Disease 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Synergy (NASDAQ: SNYR) Strategic Partnership w/ McKesson (NYSE: MCK) Sends “FOCUSfactor” Exploding Across North America – More Stocks Inside
Via AB Newswire
ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
Webcast of virtual fireside chat today, June 17th, at 7:00 a.m. ET 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Announces First Quarter 2025 Financial Results
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer’s Disease/Parkinson’s Disease 2025 International Conference
Multiple datasets support continued development of ProMIS’ antibody therapeutics and vaccines that selectively target toxic misfolded proteins to treat neurodegenerative diseases 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences to Participate in the 37th Annual Roth Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Issues Letter to Shareholders
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer’s Disease
Targeting toxic oligomers without binding to plaque, designed to reduce the risk of ARIA and potentially deliver enhanced outcomes for patients 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences to Participate in 7th Annual Evercore HealthCONx Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
From ProMIS Neurosciences Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.